SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics announced a best-efforts public offering of common…

Outlook Therapeutics, Inc. · PRESS-RELEASE filed Mar 23, 2026 at 17:30 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Mar 23, 2026 at 17:30 ET

Outlook Therapeutics announced a best-efforts public offering of common stock or pre-funded warrants, along with accompanying warrants, to raise capital for working capital and general corporate purposes. The offering is being managed by H.C. Wainwright & Co. and is subject to market conditions with no guaranteed size or completion. This is a dilutive capital raise by a small-cap biopharma company without commercial revenue in the U.S.

  • Outlook Therapeutics (OTLK) is conducting a best-efforts public offering of common stock or pre-funded warrants and accompanying warrants.
  • H.C. Wainwright & Co. is the exclusive placement agent.
  • Proceeds will be used for working capital and general corporate purposes.
  • The offering is made under a shelf registration (Form S-3) effective April 5, 2024.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access